Hedge funds specializing in life sciences and health care stocks continue to have a rough time.
While several of these funds generated small gains in the third quarter, most of them remain solidly in the red for the year.
Many of them focus on very volatile drug and biopharma stocks that are trying to get regulatory approval for their first major products.
Through
